About Eyevensys
Eyevensys created in 2009 is headquartered in Paris, France. It develops and will commercialize patented, minimally invasive, targeted, non-viral gene therapy-based solutions for the sustainable intraocular production of any secreted therapeutic protein or peptide. EYEVENSYS’s technology consists of a patented device that allows the calibrated injection in the ciliary muscle of a plasmid containing the gene encoding for a therapeutic peptide or protein. The sustainability of the gene expression is induced thanks to a patented proprietary electrotransfer technology or corticostranfection technology. The ciliary muscle is used for the transfection of therapeutic genes, playing then the role of a “factory” for the intraocular production of gene therapies, that will spread to the overall eye sphere, particularly into the vitreous cavity.
|
|
|
1-10 employees
View all Eyevensys employees
|
|
Biotechnology Research
|
|
Paris, Ile-de-France
|
|
2009
|
Eyevensys Alternatives
Frequently Asked Questions about Eyevensys
The decision makers in Eyevensys are Gina Pinto, etc. Click to Find Eyevensys decision makers emails.
Eyevensys Staff Directory
Search Eyevensys Staff Directory
Find accurate personal emails, work emails and phone numbers for employees
Supercharge your
Prospecting &
Outreach with
ContactOut
Supercharge your Prospecting &
Outreach with ContactOut
Find countless prospects outside of LinkedIn fast
Accelerate prospecting with instant access to 350M professionals from 40M companies with the right contact details.
